Cited 11 times in
Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강창무 | - |
dc.date.accessioned | 2020-12-01T17:01:44Z | - |
dc.date.available | 2020-12-01T17:01:44Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180091 | - |
dc.description.abstract | Background: Non-randomized studies have investigated multi-agent gemcitabine-based neo-adjuvant therapies (GEM-NAT) in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC). Treatment sequencing and specific elements of neoadjuvant treatment are still under investigation. The present meta-analysis aims to assess the effectiveness of GEM-NAT on overall survival (OS) in BR-PDAC. Patients and Methods: A meta-analysis of individual participant data (IPD) on GEM-NAT for BR-PDAC were performed. The primary outcome was OS after treatment with GEM-based chemotherapy. In the Individual Patient Data analysis data were reappraised and confirmed as BR-PDAC on provided radiological data. Results: Six studies investigating GEM-NAT were included in the IPD metanalysis. The IPD metanalysis was conducted on 271 patients who received GEM-NAT. Pooled median patient-level OS was 22.2 months (95%CI 19.1-25.2). R0 rates ranged between 81 and 95% (I 2 = 0%, p = 0.64), respectively. Median OS was 27.8 months (95%CI 23.9-31.6) in the patients who received NAT-GEM followed by resection compared to 15.4 months (95%CI 12.3-18.4) for NAT-GEM without resection and 13.0 months (95%CI 7.4-18.5) in the group of patients who received upfront surgery (p < 0.0001). R0 rates ranged between 81 and 95% (I 2 = 0%, p = 0.64), respectively. Overall survival in the R0 group was 29.3 months (95% CI 24.3-34.2) vs. 16.2 months (95% CI 7·9-24.5) in the R1 group (p = 0·001). Conclusions: The present study is the first meta-analysis combining IPD from a number of international centers with BR-PDAC in a cohort that underwent multi-agent gemcitabine neoadjuvant therapy (GEM-NAT) before surgery. GEM-NAT followed by surgical resection improve survival and R0 resection in BR-PDAC. Also, GEM-NAT may result in a good palliative option in non-resected patients because of progressive disease after neoadjuvant treatment. Results from randomized controlled trials (RCTs) are awaited to validate these findings. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Frontiers Research Foundation | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Francesco Giovinazzo | - |
dc.contributor.googleauthor | Fiammetta Soggiu | - |
dc.contributor.googleauthor | Jin-Young Jang | - |
dc.contributor.googleauthor | Eva Versteijne | - |
dc.contributor.googleauthor | Geertjan van Tienhoven | - |
dc.contributor.googleauthor | Casper H van Eijck | - |
dc.contributor.googleauthor | Youngmin Han | - |
dc.contributor.googleauthor | Seong Ho Choi | - |
dc.contributor.googleauthor | Chang Moo Kang | - |
dc.contributor.googleauthor | Mark Zalupski | - |
dc.contributor.googleauthor | Hasham Ahmad | - |
dc.contributor.googleauthor | Sarah Yentz | - |
dc.contributor.googleauthor | Scott Helton | - |
dc.contributor.googleauthor | J Bart Rose | - |
dc.contributor.googleauthor | Chie Takishita | - |
dc.contributor.googleauthor | Yuichi Nagakawa | - |
dc.contributor.googleauthor | Mohammad Abu Hilal | - |
dc.identifier.doi | 10.3389/fonc.2020.01112 | - |
dc.contributor.localId | A00088 | - |
dc.relation.journalcode | J03512 | - |
dc.identifier.eissn | 2234-943X | - |
dc.identifier.pmid | 32850319 | - |
dc.subject.keyword | Borderline resectable pancreaic adenocarcinoma | - |
dc.subject.keyword | Pancreatic ductal adenocancinoma | - |
dc.subject.keyword | gemcitabine | - |
dc.subject.keyword | gemcitabine-based neoadjuvant | - |
dc.subject.keyword | neoadjuvant treatment of pancreatic cancer | - |
dc.contributor.alternativeName | Kang, Chang Moo | - |
dc.contributor.affiliatedAuthor | 강창무 | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 1112 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, Vol.10 : 1112, 2020-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.